Ascendis Pharma A/S (ASND) has disclosed a new risk, in the Natural and Human Disruptions category.
Ascendis Pharma A/S faces significant business risk from ongoing and potential future health crises, such as the COVID-19 pandemic, which disrupts operations and the financial markets critical for capital access. The pandemic’s implications, including governmental measures like lockdowns and travel bans, directly threaten the continuity of clinical trials, supply chains, and commercial activities. These disruptions also extend to Ascendis Pharma’s partners and stakeholders, potentially affecting their workforce and interactions with regulators. The full impact of COVID-19 remains unpredictable, with financial market volatility and potential recession posing additional threats to the company’s stability and the value of its ADSs.
The average ASND stock price target is $174.60, implying 25.39% upside potential.
To learn more about Ascendis Pharma A/S’ risk factors, click here.
